{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:35:28Z","timestamp":1782218128697,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the real\u2010world effectiveness and safety of insulin glargine 300\u2009U\/ml (Gla\u2010300) in achieving glycaemic goals in insulin\u2010na\u00efve people with type 2 diabetes (T2D) in Mexico, Colombia and Peru (Latin America region) in the A Toujeo Observational Study (ATOS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>ATOS was a multicentre, prospective, 12\u2010month observational study, which included 4422 insulin\u2010na\u00efve adults (age \u2265\u200918\u2009years) with T2D uncontrolled (HbA1c &gt;\u20097% and \u226411%) on at least one oral antidiabetic drug (OAD) who initiated Gla\u2010300 treatment as per routine practice. The primary endpoint was the percentage of participants achieving their predefined individualized HbA1c goal at month 6. Key secondary endpoints included change from baseline in HbA1c, fasting plasma glucose (FPG), fasting self\u2010monitored blood glucose (SMBG), body weight and incidence of hypoglycaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this subgroup analysis, a total of 314 participants with T2D received Gla\u2010300. At baseline, mean\u2009\u00b1\u2009SD age was 56.0\u2009\u00b1\u200911.6\u2009years, duration of diabetes was 9.7\u2009\u00b1\u20096.6\u2009years and 65.9% of participants were on at least two OADs. The individualized HbA1c target was achieved by 25.8% of participants (95% confidence interval [CI]: 20.3\u201031.9) at month 6 and by 35.3% (95% CI: 28.5\u201042.5) at month 12. Gla\u2010300 treatment improved glycaemic control with meaningful reductions in mean HbA1c, FPG and fasting SMBG. The incidence of hypoglycaemia reported was low and body weight remained stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real\u2010world setting in the Latin America region, the initiation of Gla\u2010300 in people with T2D uncontrolled on OADs resulted in improved glycaemic control with a low incidence of hypoglycaemia and no change in body weight.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14868","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T11:57:47Z","timestamp":1663156667000},"page":"238-247","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["<scp>Real\u2010world<\/scp>\n                    effectiveness and safety of insulin glargine 300\u00a0\n                    <scp>U\/ml<\/scp>\n                    in\n                    <scp>insulin\u2010na\u00efve<\/scp>\n                    people with type 2 diabetes in the\n                    <scp>Latin America<\/scp>\n                    region: A subgroup analysis of the\n                    <scp>ATOS<\/scp>"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-7378","authenticated-orcid":false,"given":"Hernando","family":"Vargas\u2010Uricoechea","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine Universidad del Cauca  Popayan Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Burga Nu\u00f1ez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Arequipa \u2013 EXACTA LAB SAC  Yanahuara Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rosas Guzm\u00e1n","sequence":"additional","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas de Celaya  Guanajuato Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-3616","authenticated-orcid":false,"given":"Liliana","family":"Silva\u2010Gomez","sequence":"additional","affiliation":[{"name":"Medical Department Sanofi  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Beltran","sequence":"additional","affiliation":[{"name":"Medical Department Sanofi  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8463-462X","authenticated-orcid":false,"given":"Mar\u00eda Elena","family":"Sa\u00f1udo\u2010Maury","sequence":"additional","affiliation":[{"name":"Medical Department Sanofi  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,9]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"112","article-title":"Diabetes in Latin America: prevalence, complications, and socio\u2010economic impact","volume":"6","author":"Sinisterra\u2010Loaiza L","year":"2019","journal-title":"Int J Diabetes Clin Res."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2020.10.001"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183953"},{"key":"e_1_2_9_5_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation (IDF)","year":"2021"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009"},{"key":"e_1_2_9_7_1","unstructured":"Association of Latin America Diabetes.ALAD guidelines on the diagnosis control and treatment of type 2 diabetes mellitus with medicine based on evidence.2019.https:\/\/wwwrevistaaladcom\/guias\/5600AX191_guias_alad_2019.pdf. Accessed March 25 2022."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1020-49892007000600002"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-01341-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1020-49892010001200008"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237542"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00961-4"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0991"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12485"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13936"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12532"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0559"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1708287"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13199"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0568-8"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01266-4"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13693"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13793"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13952"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0435"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S006"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.17218"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05080-9"},{"key":"e_1_2_9_33_1","unstructured":"MikkelsenB.Introducing the Global Diabetes Compact.2021.https:\/\/wwwwhoint\/publications\/m\/item\/introducing-the-global-diabetes-compact. Accessed October 14 2021."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/19322968211034533"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:30:33Z","timestamp":1761877833000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/dom.14868"],"URL":"https:\/\/doi.org\/10.1111\/dom.14868","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14868\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14868\/v1\/review4","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,9]]},"assertion":[{"value":"2022-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}